Cell and Gene Supply Chain Services Market Size & Share, By Technology (Presence on cloud, Presence on-premises), Application (Ordering and Scheduling, Sample Collection, Logistics, Post Treatment Follow-up), End User (Biobank/ Cell-bank, Hospitals, Research Institutes, Cell Therapy Labs, Others), Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Market Outlook:

Cell and Gene Supply Chain Services Market exceeded USD 1.42 Billion in 2023 and is expected to exceed USD 3.49 Billion by end of the year 2032, observing around 10.5% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 1.42 Billion
• CAGR (2024-2032): 10.5%
• Forecast Year Value (2032): USD 3.49 Billion
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

The increasing demand for personalized medicine and the rise in funding for cell and gene therapy research are major growth drivers for the Cell and Gene Supply Chain Services Market. Additionally, advancements in technology and the development of innovative therapies are driving the market forward.

Report Scope

Report Coverage	Details
Segments Covered	Technology, Application, End User
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Biocair, Arvato Supply Chain Solutions SE, Associated Couriers, LLC., TrakCel, ParkourSC, DHL, McKesson, Almac, Catalent, Biostor.

Industry Restraints:

The stringent regulations and challenges in supply chain logistics act as restraints for the Cell and Gene Supply Chain Services Market. The complex nature of these therapies also poses challenges for manufacturers and service providers.

Regional Forecast:

North America: The Cell and Gene Supply Chain Services market size in North America, specifically the United States and Canada, is experiencing rapid growth due to increasing investments in biotechnology research and development. The region is home to several leading biopharmaceutical companies and research institutions, driving the demand for supply chain services. The presence of advanced healthcare infrastructure and regulatory frameworks further contribute to the expansion of the market in North America.

Asia Pacific: In Asia Pacific, countries such as China, Japan, and South Korea are witnessing a surge in the cell and gene supply chain services market. The region is known for its robust manufacturing capabilities and growing biotechnology sector. Increasing investments in healthcare infrastructure and research facilities are propelling the demand for supply chain services in Asia Pacific. In addition, favorable government initiatives and collaborations with global pharmaceutical companies are driving the growth of the market in the region.

Europe: The Cell and Gene Supply Chain Services market in Europe, particularly in the United Kingdom, Germany, and France, is witnessing steady growth. The region has a strong presence of biopharmaceutical companies, academic institutions, and research organizations, fostering the demand for supply chain services. Stringent regulatory standards and a focus on innovation and research are key factors driving the market in Europe. Additionally, strategic collaborations and partnerships between stakeholders are further fueling the growth of the market in the region.

Segmentation Analysis:

In terms of segmentation, the global Cell and Gene Supply Chain Services market is analyzed on the basis of Technology, Application, End User.

Cell and Gene Supply Chain Services Market

Presence on cloud vs. Presence on-premises:

The cell and gene supply chain services market can be segmented based on the technology used, with options including presence on cloud or presence on-premises. Depending on the specific needs of the end user, companies may opt for cloud-based solutions for easier accessibility and scalability, or choose on-premises solutions for enhanced security and control over data.

Ordering and Scheduling:

One key application within the cell and gene supply chain services market is ordering and scheduling. This involves streamlining the process of placing orders for cells or gene therapy products, as well as scheduling the delivery and logistics for these orders. Efficiency in ordering and scheduling can significantly impact the overall supply chain performance.

Sample Collection:

Another important application in this market is sample collection. This involves the collection, storage, and transportation of biological samples for cell and gene therapy purposes. Effective sample collection processes are crucial for maintaining sample integrity and ensuring the success of downstream processes.

Logistics:

Logistics play a critical role in the cell and gene supply chain services market, encompassing the movement of materials, products, and information throughout the supply chain. Efficient logistics management is essential for ensuring timely and accurate delivery of cell and gene therapy products to the end user.

Post Treatment Follow-up:

Post-treatment follow-up is an essential aspect of cell and gene therapy, ensuring that patients receive appropriate monitoring and care after receiving treatment. This segment of the market focuses on providing support services for patients, clinicians, and researchers to monitor treatment outcomes and adjust therapies as needed.

Biobank/Cell-bank, Hospitals, Research Institutes, Cell Therapy Labs, Others:

The end user segment of the cell and gene supply chain services market includes various entities such as biobanks/cell banks, hospitals, research institutes, and cell therapy labs. Each of these end users has unique supply chain requirements and challenges, necessitating tailored solutions to meet their specific needs.

Competitive Landscape:

The competitive landscape in the Cell and Gene Supply Chain Services Market is characterized by rapid advancements and a growing emphasis on personalized medicine. As therapies such as CAR-T and gene therapies continue to evolve, supply chain service providers are focusing on enhancing logistical capabilities, regulatory compliance, and technology integration to meet the unique demands of these complex products. Players in this market are leveraging innovations in cold chain management, real-time tracking, and data analytics to optimize distribution processes. Additionally, strategic partnerships and collaborations are prevalent as companies aim to expand their service offerings and geographical reach. The landscape remains dynamic, with emerging players constantly entering the market to address evolving customer needs and regulatory challenges.

Top Market Players

- Thermo Fisher Scientific

- Catalent, Inc.

- Parexel International Corporation

- Schumacher Clinical Partners

- Lonza Group AG

- Erytech Pharma

- WuXi AppTec

- BioLife Sciences

- Syneos Health

- OptiFreight Logistics